---
schema_version: "secwatch.filing_event.v1"
accession: "0001640334-26-001437"
form_type: "8-K"
ticker: "LEXX"
cik: "0001348362"
company_name: "Lexaria Bioscience Corp."
filed_at: "2026-09-01T13:16:32+00:00"
generated_at: "2026-09-01T13:17:36.792852+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Lexaria receives AUD$3.67M Australian R&D tax credit for GLP-1 clinical study

## Summary
- Received AUD$3,666,611.98 (USD$2.6M) R&D tax credit from Australian Tax Office on Aug 28, 2026.
- Credit relates to clinical study GLP-1-H24-4 conducted by Lexaria (AU) Pty Ltd, wholly-owned subsidiary.
- Funds deposited in Australian bank account to pursue additional R&D opportunities in Australia.
- Subsidiary holds exclusive DehydraTECH rights for pharmaceutical GLP-1/GIP and CBD drugs in Australia.

## SEC filing metadata
- accession: 0001640334-26-001437
- form_type: 8-K
- ticker: LEXX
- cik: 0001348362
- company_name: Lexaria Bioscience Corp.
- filed_at: 2026-09-01T13:16:32+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1348362/000164033426001437/0001640334-26-001437-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1348362/000164033426001437/lxrp_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001640334-26-001437
- JSON: https://secwatch.observer/filing/0001640334-26-001437.json
- Plain text: https://secwatch.observer/filing/0001640334-26-001437.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.